We have helped 100+ companies launch


We are a Tucson, Arizona based non-profit organization of accredited investors who seek opportunities to invest in Southwest regional startup or early stage companies.

85+

angel investors

$
50m+

funded

115

portfolio companies

Present your Company

The DESERT ANGELS ™ welcomes applications from startup or early stage companies. We evaluate applications on an ongoing basis and meet monthly from September through June.

Present your company
Created with Sketch.

Become a member

As a vibrant, growing organization, the DESERT ANGELS ™ welcomes new members. If you are an accredited investor with a tenacious appetite for helping early-stage companies succeed, we’d love to get to know you better at an upcoming dinner meeting.

Join now
Created with Sketch.
January 22, 2018

It is safe to say that there would have been no Calimmune without the early support of the Desert Angels.

Many members of the DA share our passion and see the potential for gene therapy to transform healthcare and liberate patients from chronic and incurable diseases. Their investments have helped us grow this company to what it is today. We truly hope Calimmune’s work will be life-changing for the people we plan to serve and the investors that supported us.

LOUIS BRETON - CEO | CALIMMUNE
Calimmune has assembled a world-class team of researchers, clinicians and translational experts in related fields of science and medicine to develop innovative cell-based therapies for HIV.

Latest News and Updates

Positive results of NuvOx Pharma’s NVX-208 in the treatment of stroke have been published at the International Stroke Conference.  The trial was sponsored by the University of Arkansas for Medical Sciences. William “Bill” Culp, MD, the principal investigator on the trial, said, “Such strong safety and promising efficacy results meet our highest hopes for this […]

Keep reading

Tempe-based GT Medical Technologies Inc. received FDA approval to use its GammaTile Therapy in patients with recurrent brain tumors.  The company’s new FDA-approved procedure replaces the need for months of radiation following brain surgery. The first surgical procedure using the product was conducted Jan. 30. https://www.bizjournals.com/phoenix/news/2019/02/04/tempe-cancer-treatment-firm-gets-10m-financing.html

Keep reading

Stimwave Technologies, the leading innovator of wireless medical device bioelectronic technology, today announced pending publication and completion of long-term clinical data from the SURF study. The SURF RCT study, a prospective, randomized, multi-center clinical trial was the first ever pivotal study conducted utilizing a wirelessly powered Spinal Cord Stimulator (SCS) system comparing a variety of […]

Keep reading